A Predictive Model of Rectal Tumor Response to Preoperative Radiotherapy Using Classification and Regression Tree Methods
暂无分享,去创建一个
Nilima Nigam | Russell Steele | Inti Zlobec | R. Steele | C. Compton | I. Zlobec | N. Nigam | Carolyn C. Compton
[1] C. Reinhold,et al. Conformal Preoperative Endorectal Brachytherapy Treatment for Locally Advanced Rectal Cancer , 2002, Diseases of the colon and rectum.
[2] K. Maeda,et al. Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis , 1997, International journal of cancer.
[3] Ricky T. Tong,et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.
[4] J. Harmey,et al. Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.
[5] H. Grönberg,et al. A Systematic Overview of Radiation Therapy Effects in Rectal Cancer , 2003, Acta oncologica.
[6] T. Hwang,et al. Differential, stage‐dependent expression of Hsp70, Hsp110 and Bcl‐2 in colorectal cancer , 2003, Journal of gastroenterology and hepatology.
[7] S. Stryker,et al. Molecular markers and prediction of response to chemoradiation in rectal cancer. , 2001, Oncology reports.
[8] S. Leung,et al. Vascular endothelial growth factor is up‐regulated in the early pre‐malignant stage of colorectal tumour progression , 1999, International journal of cancer.
[9] R. Broll,et al. Vascular endothelial growth factor (VEGF)--a valuable serum tumour marker in patients with colorectal cancer? , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[10] F. Ciardiello,et al. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma , 2004, Cancer.
[11] S. Baldus,et al. Prognostic impact of p21/waf1/cip1 in colorectal cancer , 2000, International journal of cancer.
[12] G. Thomas,et al. Prognostic value of P53 mutations in rectal carcinoma , 2002, International journal of cancer.
[13] P. Farmer,et al. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1 , 2002, British Journal of Cancer.
[14] S. Yun,et al. p53, BCL-2, and Ki-67 Expression According to Tumor Response After Concurrent Chemoradiotherapy for Advanced Rectal Cancer , 2001, Annals of Surgical Oncology.
[15] A Hartz,et al. The inexact use of Fisher's Exact Test in six major medical journals. , 1989, JAMA.
[16] S. Arii,et al. Implication of vascular endothelial growth factor and p53 status for angiogenesis in noninvasive colorectal carcinoma , 2000, Cancer.
[17] B. Gastman,et al. Apoptosis and its clinical impact , 2001, Head & neck.
[18] T. Aoki,et al. Induction of apoptosis by p53, bax, bcl-2, and p21 expressed in colorectal cancer , 2003, International Journal of Clinical Oncology.
[19] S. Omatu,et al. Pattern recognition with neural networks , 2000, IGARSS 2000. IEEE 2000 International Geoscience and Remote Sensing Symposium. Taking the Pulse of the Planet: The Role of Remote Sensing in Managing the Environment. Proceedings (Cat. No.00CH37120).
[20] R. Pötter,et al. TP53 Genotype but Not p53 Immunohistochemical Result Predicts Response to Preoperative Short-Term Radiotherapy in Rectal Cancer , 2002, Annals of surgery.
[21] D. Bouchier-Hayes,et al. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells , 2001, British Journal of Cancer.
[22] D. Rothenberger,et al. Molecular prognostic factors in rectal cancer treated by radiation and surgery , 2000, Diseases of the colon and rectum.
[23] R. Salgado,et al. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma , 2004, Cancer.
[24] M. Nozue,et al. Over-expression of vascular endothelial growth factor after preoperative radiation therapy for rectal cancer. , 2001, Oncology reports.
[25] C. Vagianos,et al. bcl-2/bax Ratio as a Predictive Marker for Therapeutic Response to Radiotherapy in Patients With Rectal Cancer , 2001, Applied immunohistochemistry & molecular morphology : AIMM.
[26] R. Bristow,et al. The p53 protein family and radiation sensitivity: Yes or no? , 2004, Cancer and Metastasis Reviews.
[27] M. Gregor,et al. Influence of p53 status on prognosis in preoperatively irradiated rectal carcinoma , 1999, Cancer.
[28] H. McLeod,et al. Analysis of key cell‐cycle checkpoint proteins in colorectal tumours , 2002, The Journal of pathology.
[29] G. Viale,et al. p21WAF1/CIP1 expression in colorectal carcinoma correlates with advanced disease stage and p53 mutations , 1999, The Journal of pathology.
[30] H. Nielsen,et al. Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma , 2000 .
[31] Napoleone Ferrara,et al. Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.
[32] R. D'Amato,et al. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. , 2001, Journal of the National Cancer Institute.
[33] P. Adeleine,et al. Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: the lyon R96-02 randomized trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] H. Chung,et al. Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis , 2000, Oncogene.
[35] R. Newcombe,et al. Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging? , 2004, British Journal of Cancer.
[36] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[37] F. Ciardiello,et al. Determination of Molecular Marker Expression Can Predict Clinical Outcome in Colon Carcinomas , 2004, Clinical Cancer Research.
[38] J. Liu,et al. Apoptosome dysfunction in human cancer , 2004, Apoptosis.
[39] J. Dahm-Daphi. p53: Biology and Role for Cellular Radiosensitivity , 2000, Strahlentherapie und Onkologie.
[40] L. Påhlman,et al. Local recurrence rate in a randomized multicentre trial of preoperative radiotherapy compared to surgery alone in resectable rectal carcinoma. , 1996 .
[41] K. Hess,et al. p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[42] T. Pawlik,et al. Role of cell cycle in mediating sensitivity to radiotherapy. , 2004, International journal of radiation oncology, biology, physics.
[43] L Påhlman,et al. Improved survival with preoperative radiotherapy in resectable rectal cancer. , 1997, The New England journal of medicine.
[44] Rainer Fietkau,et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.
[45] G. Hospers,et al. Molecular prognostic factors in locally irresectable rectal cancer treated preoperatively by chemo-radiotherapy. , 2004, Anticancer research.
[46] W. Curran,et al. Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy. , 2004, Anticancer research.
[47] S. Barni,et al. An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation , 2002, British Journal of Cancer.